Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 18, 2005 Stephen D. Simpson	Kensey Nash Needs to Kick It Up The med-tech company must deliver profit growth if it is to grow or maintain its valuation.
The Motley Fool January 30, 2006 Stephen D. Simpson	Don't Hold Your Breath for Kensey Nash It's not over for Kensey Nash -- it will soon be seeing revenue from new partners Medtronic and Zimmer. But the stock's price continues to value this company as a growing med-tech idea.
The Motley Fool August 17, 2007 Rich Smith	Foolish Forecast: Kensey Turn It Around? Analysts are looking for just a modest sales increase from Kensey Nash, maker of bio-absorbable arterial sealants, but Kensey hasn't met a target yet this year.
The Motley Fool January 18, 2012 Dan Caplinger	Has St. Jude Medical Become the Perfect Stock? St. Jude took a big step toward perfection when it initiated a big dividend in early 2011.
The Motley Fool January 27, 2006 Rich Smith	Foolish Forecast: Kensey Grow or Not? The medical technology company's problem is that when you hold your margins more or less steady while your revenues also remain roughly the same, well, everything stays the same. In other words, you can't grow earnings. Investors, take note.
The Motley Fool October 17, 2005 Stephen D. Simpson	A Busy Day for St. Jude In addition to announcing a major acquisition, St. Jude also reported very solid financial results for the third quarter. Analysts keep raising the bar, and the medical equipment company continues to surpass it.
The Motley Fool August 21, 2006 Stephen D. Simpson	Kensey Nash Losing the Benefit of the Doubt Med-tech investors won't wait indefinitely for growth. Investors can find better values in this sector if they're willing to roll up their sleeves for some due diligence.
The Motley Fool January 21, 2005 Stephen D. Simpson	Kensey's Guidance Falls Just Short Small-cap medical device maker posts an "OK" quarter when the market wants "great."
The Motley Fool October 26, 2004 Rich Smith	Kensey's Questionable Call Biomedical products maker Kensey Nash forgets that it is worse to dilute and then buy back shares than never to have diluted at all.
The Motley Fool August 20, 2004 Rich Smith	Let Kensey Cure Your Portfolio The biomedical products maker is a profit-making machine. This small cap reported outsized profits for fiscal 2004.
The Motley Fool March 17, 2005 Stephen D. Simpson	(G)Nashing of Teeth at Kensey Lower guidance and slower-than-expected FDA approval of TriActiv continue to bedevil this medical device maker.
The Motley Fool April 22, 2004 Rich Smith	Kensey Nash Heals Fast Four months was all it took to rejuvinate biomedical products maker Kensey Nash's profit machine.
The Motley Fool July 20, 2005 Stephen D. Simpson	Hey, Jude! Party Hearty St. Jude's ICD (implantable cardioverter defibrillator) business is on fire and fueling strong profit growth for this medical device maker. Whether your cut-off makes St. Jude a mid-cap or a large-cap, this company is certainly growing -- and the stock's valuation reflects that.
The Motley Fool April 24, 2006 Stephen D. Simpson	Kensey Nash: Now the Comeback Kid? Strong results from a new device might be reason for optimism. Investors should still keep an eye on the valuations here and err on the side of cheapness.
The Motley Fool January 9, 2007 Billy Fisher	St. Jude's Juiced-Up Q4 The medical-device maker shows stronger vital signs. Investors, take note.
The Motley Fool October 19, 2007 Billy Fisher	Keeping Pace at St. Jude Medical device maker St. Jude Medical has a strong quarter, but investors weren't impressed.
The Motley Fool April 11, 2008 Brian Orelli	St. Jude's Heartfelt Acquisition Medical-device maker St. Jude purchases tiny EP MedSystems.
The Motley Fool April 5, 2006 Stephen D. Simpson	St. Jude's Racing Heartbeat Slows Even though the stock got far too expensive, this is still a good company and could still be a viable target for certain large health-care companies that may be in an acquisition frame of mind.
The Motley Fool October 17, 2005 Stephen D. Simpson	A Stimulating Merger St. Jude will be paying $61.25 a share in cash for Advanced Neuromodulation Systems, a robust 30% premium to Friday's closing price. This deal demonstrates that large med-tech players may still be on the prowl for avenues into fast-growing new markets.
The Motley Fool July 18, 2008 Brian Orelli	St. Jude Is a Fighter The medical device maker continues to kick the competition while it's down.
The Motley Fool April 19, 2007 Billy Fisher	A Saintly Quarter Shares of St. Jude Medical rise after the company announces a big quarter.
BusinessWeek March 22, 2004 Robert Barker	St. Jude: An Insider Sign To Investors? St. Jude, the patron saint of lost causes, rarely has needed to look out for his namesake, St. Jude Medical (STJ ). Since its birth in 1976, this maker of artificial heart valves, defibrillators, catheters, and sundry other cardiac devices has led a blessed life. It's in excellent health today. So why are insiders dumping the stock?
The Motley Fool January 25, 2006 Stephen D. Simpson	Is St. Jude Next to Be Wooed? Can St. Jude build upon the jump-start opportunity from Guidant's troubles, or will further market share growth prove to be increasingly hard to come by? Investors, take note.
The Motley Fool April 20, 2005 Stephen D. Simpson	St. Jude's Healthy Heartbeat Medical device maker St. Jude continues to be boosted by ICD market share gains, and new businesses are coming on line, as well.
The Motley Fool April 19, 2006 Stephen D. Simpson	St. Jude Lives and Learns Though dynamics in the ICD market caught it by surprise, this is still a quality med-tech company. Investors, take note.
BusinessWeek June 7, 2004 Gene G. Marcial	St. Jude's Bruise Should Clear Up Fast St. Jude Medical (STJ ) tumbled 2%, to $73, after it revealed that the FDA had delayed for a month the approval of its new Epic CRT-defibrillator.
The Motley Fool July 19, 2006 Stephen D. Simpson	Taking St. Jude's Pulse The ICD market is a long-term opportunity, but not a panacea. St. Jude investors should remember that this is a rough neighborhood -- product liability, FDA bureaucracy, and huge, tough competitors live here, too.
The Motley Fool July 25, 2011 Jordan DiPietro	Should You Retire With St. Jude? I can't decide for you whether or not this is the best stock for retirement, but it has passed all four tests, which is pretty impressive.
InternetNews February 3, 2010	Windows Veteran Mike Nash Leaving Microsoft Microsoft confirmed that long-time Windows stalwart, Mike Nash, corporate vice president of Windows platform strategy, is leaving effective before the end of February.
The Motley Fool April 25, 2011 Arundhati Parmar	St. Jude: New Aortic Replacement Valve Approved St. Jude gets good news.
The Motley Fool July 20, 2011 Seth Jayson	A Hidden Reason the Future Looks Bright for Kensey Nash The company may display positive inventory divergence, suggesting that management sees increased demand on the horizon.
The Motley Fool July 25, 2011 Jason Moser	Rising Star Buy: St. Jude Medical It's a good time to jump in on this medical-device maker.
The Motley Fool October 12, 2004 Jeff Hwang	The Phantom Stock Split "Boost" If St. Jude Medical's stock went up, it's not because it's worth any more.
The Motley Fool January 26, 2005 Stephen D. Simpson	St. Jude Is No Lost Cause The No. 3 cardiology company posts solid growth because of continuing implantable cardioverter defibrillator (ICD) market share gains.
The Motley Fool April 23, 2011	St. Jude, Medtronic Execs Offer Different Views on JAMA Article's Impact An article and government investigation into implant devices may or may not have played a role in each company's performance, depending on whom you ask.
The Motley Fool February 8, 2006 Tim Beyers	Who's Buying Now? Sometimes, insiders are buying for all the right reasons. Who's buying now? Dominion Resources... Goodrich Petroleum... iPass... ITT Educational Services... St. Jude Medical...
The Motley Fool June 7, 2011 Arundhati Parmar	St. Jude Medical Introduces Two Cardiac Devices in India St. Jude heads to the Subcontinent.
Fast Company February 2010	Steve Nash's Playbook Take a look at Steve Nash's portfolio: He's set up a diversified collection of 10 businesses in social media, health, and film -- and two not-for-profits.
The Motley Fool June 27, 2011 Arundhati Parmar	St. Jude Medical's Migraine Treatment: Good for Europe, but Not the U.S.? St. Jude won't comment on whether the company plans to do a second clinical trial or whether it is confident it will win approval from the FDA without it.
The Motley Fool July 12, 2011 Arundhati Parmar	FDA Allows Expansion of St. Jude Study to Treat Severe Depression St. Jude moves forward with treatment for depression.
IndustryWeek July 1, 2008 Brad Kenney	IT Leaders Want More Say in Strategy: By The Numbers IT leaders would be willing to trade jobs for a better strategic role.
The Motley Fool December 16, 2011 Brian Orelli	Biotech Royalties, Almost as Good as Cash They're flexible, and all royalties have value.
Fast Company December 2004 Sylvia Nasar	What Makes Beautiful Minds Some forms of creative genius seem unfathomable. But as the author of A Beautiful Mind tells us, that doesn't mean we can't learn from them. The book's subject, John Nash, won a Nobel Prize in 1994 for his noncooperative games theory.
The Motley Fool June 24, 2011 Arundhati Parmar	Data on St. Jude Migraine Treatment "Impressive" An effective migraine treatment would be very valuable for St. Jude.
The Motley Fool July 15, 2011 Arundhati Parmar	St. Jude Medical's Novel Heart Disease Diagnostic Tool Cleared in Europe St. Jude has an inventive new heart disease treatment.